Coinbase Global, Inc. vs Illumina, Inc. — how do they compare? Coinbase Global, Inc. trades at $150.24 (market cap $39.20B), while Illumina, Inc. trades at $193.3 (market cap $29.12B). The key difference: Coinbase Global, Inc. is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals.
| COIN | ILMN | |
|---|---|---|
Market Cap | $39.20B | $29.12B |
Sector | Technology | Health |
52-Week High | $387.27 | $205.10 |
52-Week Low | $141.09 | $91.00 |
Enterprise Value | $36.85B | $30.48B |
Signals from Pluang's Aura AI — not financial advice
COIN stock trades at $148.68, down 3.2% in the last session amid bearish technical signals and recent earnings misses. The company reported Q2 2026 revenue and EPS below expectations, marking the third consecutive quarterly loss despite achieving record 10.3% global trading volume share. Analyst sentiment remains mixed with 55% buy ratings but a Zacks strong sell designation on August 6, 2026. Technical indicators show bearish momentum with support at $141 and resistance at $152.
The outlook remains challenging with projected 2026 revenue decline to $6.3B and net loss of $988M. While the company maintains strong cash flow from operations ($2.4B in 2025) and is expanding into AI payment solutions, persistent earnings misses and crypto market volatility pose significant risks. The consensus price target of $207.20 suggests 39% upside potential if execution improves.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →